North America Anthrax Treatment Market, By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others), End User (Government Organization, Hospitals, Academic and Research Institutes, and Others) Industry Trends and Forecast to 2029.
North America Anthrax Treatment Market Analysis and Insights
North America anthrax treatment market is driven by the factors such as, rising incidence of bacterial infections, increasing research funding and the development of novel therapies for anthrax treatment and pipeline products enhances its demand as well as rising investment in research and development leads to the market growth. Currently, healthcare expenditure has increased across developed and emerging countries that is expected to create a competitive advantage for manufacturers to develop new and innovative products.
The increase in the number of people suffering from anthrax across the globe acts as one of the major factors driving the growth of the anthrax treatment market. The increase in the financial support to the researchers for developing novel interventions, and the rise in the threat of exposure to Bacillus anthracis among civilian populations and military forces accelerate the market growth. The increase in the number of research and development programs, and the rise in public-private partnerships for facilitating novel developments for innovative and effective treatment further influence the market. However, the high cost associated with the treatment and procedure as well as stringent government regulations for product approval are expected to hamper the growth for anthrax treatment market.
North America anthrax treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various region and partnership with suppliers for safe distribution of machine and drugs products are the major drivers which propelled the demand of the market in the forecast period.
North America anthrax treatment market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that North America anthrax treatment market will grow at a CAGR of 4.2% during the forecast period of 2022 to 2029.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million, Pricing in USD |
|
Segments Covered |
By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others),End User (Government Organization, Hospitals, Academic and Research Institutes, and Others) Industry Trends and Forecast to 2029 |
|
Countries Covered |
U.S., Canada, Mexico |
|
Market Players Covered |
Alembic Pharmaceuticals, Integrated Bio Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Bayer AG, Pfizer Inc., EMERGENT, Sanofi, Elusys Therapeutics, Lupin, Soligenix, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., INDOCO REMEDIES LTD., Paratek Pharmaceuticals, Inc., BlueWillow Biologics., Altimmune, among others |
North America Anthrax Treatment Market Dynamics
Market Definition
Anthrax is caused by a bacterium called Bacillus anthracis (B. anthracis). It is primarily a disease of livestock that become infected by ingesting spores found in soil. Humans usually become infected with anthrax by handling products of infected animals such as leather or wool or by inhaling anthrax spores from infected animal products. They can also become infected by eating undercooked meat from infected animals. Anthrax is not known to be spread person-to-person.
Three clinical forms of anthrax infection exist. Cutaneous anthrax is the most common, constituting over 95% of reported cases. An estimated 2000 cases of cutaneous anthrax occur worldwide annually and result from the entry of spores through skin abrasions.
The differential diagnosis of anthrax includes depending on the clinical features, relevant specimens include PCR, gram stain, and cultures, from blood, pleural fluid, site of ulceration, cerebrospinal, and stool. A number of available techniques are available. Most assays are based on detecting the entire organism, organism antigens, or organism nucleic acid through one of the following techniques: culture-based conventional methods; immunological detection; nucleic-acid-based assays; ligand-based detection; and biosensors.
Drivers
- Increasing Prevalence of Anthrax Infections
The incidence of bacterial infections is increasing worldwide. Anthrax is a bacterial infection caused by Bacillus anthracis which is an aerobic, gram-positive spore-forming bacterium. Depending on the route of entry of B. anthracis spores, it occurs primarily as a cutaneous, pulmonary, or gastrointestinal infection. A characteristic black, crusty spot develops on the affected skin area later and, after a few weeks, begins to loosen and ultimately falls off, leaving a scar. The course of these events is so characteristic that the diagnosis is not often missed by physicians familiar with the disease, even though it is rare. Pulmonary anthrax is the most lethal of the three types of anthrax in which, the spores once inhaled germinate within the tracheobronchial lymph nodes and multiply. Anthrax is a harmful disease that affects both humans and animals. It is a life-threatening infection caused by Bacillus anthracis. Thus, this increasing incidence and prevalence of anthrax infections has developed a need of more diagnostic approaches with increased sensitivity that can detect infection in low volume.
The increase in the number of people suffering from anthrax across the globe acts as one of the major factors driving the growth of anthrax treatment market. The increase in the financial support to the researchers for developing novel intervention, and rise in threat of exposure to Bacillus anthracis among civilian populations and military forces accelerate the market growth. The increase in the number of research and development programs, and rise in public-private partnerships for facilitating novel developments for the innovative and effective treatment further influence the market.
- Increasing Research Funding and the development of novel therapies for anthrax treatment population
Research and development is a prerequisite in order to modify the procedure intended to treat different kinds of patients. The demand of anthrax treatment is increasing worldwide involving every country. This is why the companies are continuously focusing towards research and development in order to achieve success in providing effective treatment to patients. In these recent years many diagnostic approaches have come forward to take diagnosis to new steps, and many are being made to detect even the lowest volume of parasite in human body.
These new approaches in diagnosis will take the market forward. With the increase in research funding and the development of novel therapies for the treatment of anthrax. There are several novel and pre-existing antibiotics, as well as toxin inhibitors that have shown increasing promise that targets both bacterial growth as well as toxin production for effectively work against anthrax bacterium.
As the companies are constantly engaged in developmental activities more innovative products are launched in the market. The new tools developed have the efficiency to detect bacterial infection in fewer intervals of time with higher efficacy rate, which allows consumers to achieve appropriate treatment at correct time. Thus, this signifies that increasing research and development is expected as driver for the North America anthrax treatment market growth
Opportunities
- Rising product launch
Human infection is usually via contact with infected animals or animal products and may manifest as a cutaneous, inhalational, or gastrointestinal infection. The worldwide incidence of anthrax is generally increasing. Therefore, the growing patient pool of the disease across the world is demanding highly effective and advanced anthrax treatment products to minimize the risk of death owing to anthrax disease. Moreover, the healthcare systems from developed countries prefer the high advancement with fewer risk factors and advanced anthrax treatment products. Owing to this, major market players are highly focused on product launches.
Thus growing product launches provide highly effective and advanced medical treatment products for a better patient experience. New product launches generate attention for the company as well as create the company's presence in the North America market. The fundamental beneficial factor of the product launch is escalating the company’s business growth. Whereas new product launches create the revenue stream for the company and the revenue stream that establish with the product launch can be persistent for many years. Owing to this, it is estimated that new product launches is expected a tremendous opportunity for the market players to elevate their business growth in the anthrax treatment market.
Restraints/Challenges
- High cost of treatment
The cost of the product plays a major factor in the market. Many diagnostic options are available in the market, but due to their high cost, most people tend to avoid going for a diagnosis. Since diagnostic approaches have come with greater sensitivity and specificity cost of the test also increased. The high cost of the procedure is due to the various checkpoints of the treatments along with the use of high-tech modalities to perform such procedures. As the cost of technological advanced devices is high, the procedure cost proportionally gets escalated, due to which high cost of the procedure is expected to hamper the demand of the market.
Moreover, asymptomatic infections have to go through very specific tests for the identification of bacteria which are costly. Since the high cost of diagnosis for the anthrax, it is expected to restrain the market growth. As the cost of identification treatments is too high, it restricts physicians and patients to accommodate a high-quality and effective solution. Henceforth, the high cost of the treatment procedures has a negative impact on the cost of the overall treatment. Consequently, it will constrict the future demand for treatment in low and middle-income countries. This suggests that high-cost procedures are expected to act as a restraint on the North America anthrax treatment market growth.
Recent Development
- In June 2022, Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 which is a new anthrax vaccine candidate evaluated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age with recommended antibacterial drugs.
- In January 2022, Alembic Pharmaceuticals Limited announced that the company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg which is used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. This results in expansion of product portfolio of the company.
North America Anthrax Treatment Market Segmentation
North America anthrax treatment market is categorized into three notable segments based on type, route of administration and end user. The growth among segments helps you analyses niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Cutaneous Anthrax
- Pulmonary Anthrax
- Intestinal Anthrax
On the basis of type, the North America anthrax treatment market is segmented into cutaneous anthrax, pulmonary anthrax and intestinal anthrax.
Route of Administration
- Cutaneous Anthrax
- Pulmonary Anthrax
- Intestinal Anthrax
On the basis of route of administration, North America anthrax treatment market is segmented into oral, parenteral and others.
End User
- Government Organization
- Hospitals
- Academic and Research Institutes,
- Others
On the basis of end user, North America anthrax treatment market is segmented into government organization, hospitals, academic and research institutes, and others.
Anthrax Treatment Market Regional Analysis/Insights
The North America anthrax treatment market is analysed and market size insights and trends are provided by type, route of administration and end user as referenced above.
The countries covered in the anthrax treatment report are U.S., Canada and Mexico.
The U.S.is expected to dominate due to increasing technological advancement in the developing areas.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Anthrax Treatment Market Share Analysis
North America anthrax treatment market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on anthrax treatment market.
Some players in the market are Alembic Pharmaceuticals, Integrated Bio Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Bayer AG, Pfizer Inc., EMERGENT, Sanofi, Elusys Therapeutics, Lupin, Soligenix, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., INDOCO REMEDIES LTD., Paratek Pharmaceuticals, Inc., BlueWillow Biologics., Altimmune, among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analysed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, North America vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA ANTHRAX TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 DEMOGRAPHIC TRENDS-
4.4 EPIDEMIOLOGY AND DEMOGRAPHICS-
4.4.1 INCIDENCE
4.4.2 DEVELOPED COUNTRIES-
4.4.3 DEVELOPING COUNTRIES-
4.5 PATIENT ENROLMENT STRATEGIES-
4.6 PATIENT FLOW DIAGRAM FOR ANTHRAX INFECTION-
4.7 CURRENT STATE OF ANTHRAX VACCINES
4.8 NORTH AMERICA ANTIBIOTIC CONSUMPTION RATES INCREASED BY 46 PERCENT IN THE LAST TWO DECADES, ACCORDING TO THE FIRST STUDY TO PROVIDE LONGITUDINAL ESTIMATES FOR HUMAN ANTIBIOTIC CONSUMPTION COVERING 204 COUNTRIES FROM 2000 TO 2018.
4.9 NORTH AMERICA ANTIBIOTIC CONSUMPTION AND PROJECTED CONSUMPTION-
5 THE M&A IN THE ANTHRAX MARKET INDICATES AN UPCOMING LONG RUN IN VACCINE DEVELOPMENT AROUND THE GLOBE. CURRENT AND SOME OF LAST YEAR’S ACQUISITION BETWEEN LEADERS AND SMALL SIZE PHARMACEUTICAL SHOWS THE CONTINUOUS DEVELOPMENT IN THE COMPANY’S PIPELINE FOR ANTHRAX TREATMENT.
6 NORTH AMERICA ANTHRAX TREATMENT MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING INCIDENCE OF ANTHRAX INFECTION
7.1.2 INCREASE IN RESEARCH FUNDING AND THE DEVELOPMENT OF NOVEL THERAPIES FOR THE TREATMENT OF ANTHRAX
7.1.3 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT PROCEDURE
7.1.4 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS
7.2 RESTRAINTS
7.2.1 HIGH COST ASSOCIATED WITH ANTHRAX DIAGNOSTIC TREATMENT
7.2.2 FALSE DATA INTERPRETATION
7.3 OPPORTUNITIES
7.3.1 RISING PRODUCT LAUNCHES
7.3.2 RISING GOVERNMENT INITIATIVES
7.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM
7.4 CHALLENGES
7.4.1 LACK OF AWARENESS AMONG PEOPLE ABOUT ANTHRAX INFECTION
7.4.2 LACK OF SKILLED PROFESSIONALS
8 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 CUTANEOUS ANTHRAX
8.2.1 ANTIBIOTICS
8.2.1.1 BY DRUGS
8.2.1.1.1 CIPROFLOXACIN
8.2.1.1.2 LEVOFLOXACIN
8.2.1.1.3 DOXYCYCLINE
8.2.1.1.4 AMPICILLIN
8.2.1.1.5 OTHERS
8.2.1.2 BY PRODUCT TYPES
8.2.1.2.1 GENERICS
8.2.1.2.2 BRANDED
8.2.1.2.2.1 CIPRO
8.2.1.2.2.2 LEVO
8.2.1.2.2.3 DOXY
8.2.1.2.2.4 AMPICI
8.2.1.2.2.5 OTHERS
8.2.2 ANTITOXINS
8.2.2.1 RAXIBACUMAB
8.2.2.2 OBILTOXAXIMAB (ANTHIM)
8.2.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.2.2.4 OTHERS
8.2.3 VACCINES
8.2.3.1 RAXIBACUMAB
8.2.4 SURGERY
8.3 PULMONARY ANTHRAX
8.3.1 ANTIBIOTICS
8.3.1.1 BY DRUGS
8.3.1.1.1 CIPROFLOXACIN
8.3.1.1.2 LEVOFLOXACIN
8.3.1.1.3 DOXYCYCLINE
8.3.1.1.4 AMPICILLIN
8.3.1.1.5 OTHERS
8.3.1.2 BY PRODUCT TYPES
8.3.1.2.1 GENERICS
8.3.1.2.2 BRANDED
8.3.1.2.2.1 CIPRO
8.3.1.2.2.2 LEVO
8.3.1.2.2.3 DOXY
8.3.1.2.2.4 AMPICI
8.3.1.2.2.5 OTHERS
8.3.2 ANTITOXINS
8.3.2.1 RAXIBACUMAB
8.3.2.2 OBILTOXAXIMAB (ANTHIM)
8.3.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.3.2.4 OTHERS
8.3.3 VACCINES
8.3.3.1 RAXIBACUMAB
8.3.3.2 SURGERY
8.4 INTESTINAL ANTHRAX
8.4.1 ANTIBIOTICS
8.4.1.1 BY DRUGS
8.4.1.1.1 CIPROFLOXACIN
8.4.1.1.2 LEVOFLOXACIN
8.4.1.1.3 DOXYCYCLINE
8.4.1.1.4 AMPICILLIN
8.4.1.1.5 OTHERS
8.4.1.2 BY PRODUCT TYPES
8.4.1.2.1 GENERICS
8.4.1.2.2 BRANDED
8.4.1.2.2.1 CIPRO
8.4.1.2.2.2 LEVO
8.4.1.2.2.3 DOXY
8.4.1.2.2.4 AMPICI
8.4.1.2.2.5 OTHERS
8.4.2 ANTITOXINS
8.4.2.1 RAXIBACUMAB
8.4.2.2 OBILTOXAXIMAB (ANTHIM)
8.4.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.4.2.4 OTHERS
8.4.3 VACCINES
8.4.3.1 RAXIBACUMAB
8.4.3.2 SURGERY
9 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 PARENTERAL
9.3 ORAL
9.4 OTHERS
10 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY END USER
10.1 OVERVIEW
10.2 GOVERNMENT ORGANIZATION
10.3 HOSPITALS
10.4 ACADEMIC AND RESEARCH
10.5 OTHERS
11 NORTH AMERICA VIRTUAL REALITY MARKET, BY GEOGRAPHY
11.1 NORTH AMERICA
11.1.1 U.S.
11.1.2 CANADA
11.1.3 MEXICO
12 NORTH AMERICA ANTHRAX TREATMENT MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 BAYER AG
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 PFIZER INC.
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 TEVA PHARMACEUTICAL INDUSTRIES LTD
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 SANOFI
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.6 ALEMBIC PHARMACEUTICALS LIMITED
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENTS
14.7 ALTIMMUNE
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 ARISTO PHARMACEUTICALS PRIVATE LIMITED
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENTS
14.9 BLUEWILLOW BIOLOGICS.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 DEINOVE
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 EMERGENT
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENTS
14.12 ELUSYS THERAPEUTICS INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 GC BIOPHARMA CORP.
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENTS
14.14 INDOCO REMEDIES LTD.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 INTEGRATED BIOTHERAPEUTICS, INC.
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENTS
14.16 LUPIN.
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENTS
14.17 PARATEK PHARMACEUTICALS, INC.
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 PORTON BIOPHARMA
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENTS
14.19 SOLIGENIX
14.19.1 COMPANY SNAPSHOT
14.19.2 REVENUE ANALYSIS
14.19.3 PRODUCT PORTFOLIO
14.19.4 RECENT DEVELOPMENTS
14.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
14.21 ZYDUS GROUP
14.21.1 COMPANY SNAPSHOT
14.21.2 REVENUE ANALYSIS
14.21.3 PRODUCT PORTFOLIO
14.21.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
List of Table
TABLE 1 POPULATION AT RISK (IN MILLIONS) BY REGION, LAND USE AND OCCUPATIONAL EXPOSURE, 2020-
TABLE 2 VACCINES IN DEVELOPMENT
TABLE 3 ANTIBIOTIC CONSUMPTION ESTIMATES BY GBD SUPER-REGION AND GBD REGION, FOR THE YEAR 2018-
TABLE 4 COUNTRY DATA OF ANTIBIOTICS CONSUMPTION-
TABLE 5 RECENT M&A IN ANTHRAX MARKET-
TABLE 6 ANTIBIOTICS MEDICINES
TABLE 7 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 8 NORTH AMERICA ANTHRAX TREATMENT MARKET, TYPE, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA CUTANEOUS ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA PARENTERAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA ORAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA GOVERNMENT ORGANIZATION IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA HOSPITALS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA ACADEMIC AND RESEARCH IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY TYPE , 2020-2029 (USD MILLION)
TABLE 44 NORTH AMERICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 45 NORTH AMERICA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 46 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 47 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 48 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 49 NORTH AMERICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 50 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 51 NORTH AMERICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 52 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 53 NORTH AMERICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 54 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 55 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 56 NORTH AMERICA VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 57 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 58 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 59 NORTH AMERICA PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 60 NORTH AMERICA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 61 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 62 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 63 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 64 NORTH AMERICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 65 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 66 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 67 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 68 NORTH AMERICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 69 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 70 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 71 NORTH AMERICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 72 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 73 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 74 NORTH AMERICA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 75 NORTH AMERICA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 76 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 77 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 78 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 79 NORTH AMERICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 80 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 81 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 82 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 83 NORTH AMERICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 84 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 85 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 86 NORTH AMERICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 87 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 88 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 89 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 90 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 91 U.S. ANTHRAX TREATMENT MARKET, BY TYPE , 2020-2029 (USD MILLION)
TABLE 92 U.S. CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 93 U.S. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 94 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 95 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 96 U.S. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 97 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 98 U.S. BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 99 U.S. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 100 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 101 U.S. VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 102 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 103 U.S. PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 104 U.S. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 105 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 106 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 107 U.S. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 108 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 109 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 110 U.S. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 111 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 112 U.S. VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 113 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 114 U.S. INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 115 U.S. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 116 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 117 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 118 U.S. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 119 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 120 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 121 U.S. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 122 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 123 U.S. VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 124 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 125 U.S. ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 126 U.S. ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 127 CANADA ANTHRAX TREATMENT MARKET, BY TYPE , 2020-2029 (USD MILLION)
TABLE 128 CANADA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 129 CANADA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 130 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 131 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 132 CANADA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 133 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 134 CANADA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 135 CANADA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 136 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 137 CANADA VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 138 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 139 CANADA PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 140 CANADA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 141 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 142 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 143 CANADA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 144 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 145 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 146 CANADA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 147 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 148 CANADA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 149 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 150 CANADA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 151 CANADA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 152 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 153 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 154 CANADA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 155 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 156 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 157 CANADA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 158 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 159 CANADA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 160 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 161 CANADA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 162 CANADA ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 163 MEXICO ANTHRAX TREATMENT MARKET, BY TYPE , 2020-2029 (USD MILLION)
TABLE 164 MEXICO CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 165 MEXICO ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 166 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 167 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 168 MEXICO BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 169 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 170 MEXICO BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 171 MEXICO ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 172 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 173 MEXICO VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 174 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 175 MEXICO PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 176 MEXICO ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 177 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 178 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 179 MEXICO BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 180 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 181 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 182 MEXICO ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 183 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 184 MEXICO VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 185 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 186 MEXICO INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 187 MEXICO ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 188 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 189 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 190 MEXICO BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 191 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 192 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 193 MEXICO ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 194 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 195 MEXICO VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 196 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 197 MEXICO ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 198 MEXICO ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA ANTHRAX TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA ANTHRAX TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA ANTHRAX TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA ANTHRAX TREATMENT MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 NORTH AMERICA ANTHRAX TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA ANTHRAX TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA ANTHRAX TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA ANTHRAX TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA ANTHRAX TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA ANTHRAX TREATMENT MARKET: SEGMENTATION
FIGURE 11 MIDDLE EAST & AFRICA IS ANTICIPATED TO DOMINATE THE ANTHRAX TREATMENT MARKET AND GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING INCIDENCE AND PREVALENCE OF ANTHRAX INFECTIONS ARE EXPECTED TO DRIVE THE NORTH AMERICA ANTHRAX TREATMENT MARKET IN THE FORECAST PERIOD
FIGURE 13 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ANTHRAX TREATMENT MARKET IN 2022 & 2029
FIGURE 14 NORTH AMERICA DISTRIBUTION OF OUTBREAKS BY COUNTRY AND GEOGRAPHIC LOCATIONS OF ANTHRAX EVENTS-
FIGURE 15 PATHOPHYSIOLOGY OF ANTHRAX-
FIGURE 16 FLOW CHART FOR SUSPECTED ANTHRAX EXPOSURE-
FIGURE 17 GC BIOPHARMA ANTHRAX CANDIDATE GC1109 IS IN PHASE 2 (NCT01624532).
FIGURE 18 BA-ISTAB IS A FUSION OF A B. ANTHRACIS SPECIFIC CWT WITH A POTENT MONOCLONAL ANTIBODY THAT NEUTRALIZE ANTHRAX TOXIN (PA).
FIGURE 19 TWO ROUTES BY WHICH VACCINATION CAN REDUCE INCIDENCE OF AMR-
FIGURE 20 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA ANTHRAX TREATMENT MARKET
FIGURE 21 NORTH AMERICA ANTHRAX TREATMENT MARKET : TYPE, 2021
FIGURE 22 NORTH AMERICA ANTHRAX TREATMENT MARKET : TYPE, 2022-2029 (USD MILLION)
FIGURE 23 NORTH AMERICA ANTHRAX TREATMENT MARKET : TYPE, CAGR (2022-2029)
FIGURE 24 NORTH AMERICA ANTHRAX TREATMENT MARKET : TYPE, LIFELINE CURVE
FIGURE 25 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2021
FIGURE 26 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 27 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 28 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 29 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY END USER, 2021
FIGURE 30 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 31 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY END USER, CAGR (2022-2029)
FIGURE 32 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY END USER, LIFELINE CURVE
FIGURE 33 NORTH AMERICA ANTHRAX TREATMENT MARKET: SNAPSHOT (2021)
FIGURE 34 NORTH AMERICA ANTHRAX TREATMENT MARKET: BY COUNTRY (2021)
FIGURE 35 NORTH AMERICA ANTHRAX TREATMENT MARKET: BY COUNTRY (2022 & 2029)
FIGURE 36 NORTH AMERICA ANTHRAX TREATMENT MARKET: BY COUNTRY (2021 & 2029)
FIGURE 37 NORTH AMERICA ANTHRAX TREATMENT MARKET: BY TYPE (2022-2029)
FIGURE 38 NORTH AMERICA ANTHRAX TREATMENT MARKET: COMPANY SHARE 2021(%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
